CA3156134A1 - Anti-tirc7 antigen binding proteins - Google Patents

Anti-tirc7 antigen binding proteins

Info

Publication number
CA3156134A1
CA3156134A1 CA3156134A CA3156134A CA3156134A1 CA 3156134 A1 CA3156134 A1 CA 3156134A1 CA 3156134 A CA3156134 A CA 3156134A CA 3156134 A CA3156134 A CA 3156134A CA 3156134 A1 CA3156134 A1 CA 3156134A1
Authority
CA
Canada
Prior art keywords
tirc7
antigen
binding proteins
diseases
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3156134A
Other languages
English (en)
French (fr)
Inventor
Nalan Utku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nekonal SARL
Original Assignee
Nekonal SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nekonal SARL filed Critical Nekonal SARL
Publication of CA3156134A1 publication Critical patent/CA3156134A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3156134A 2019-09-30 2020-09-30 Anti-tirc7 antigen binding proteins Pending CA3156134A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19200324 2019-09-30
EP19200324.2 2019-09-30
PCT/EP2020/077422 WO2021073877A2 (en) 2019-09-30 2020-09-30 Anti-tirc7 antigen binding proteins

Publications (1)

Publication Number Publication Date
CA3156134A1 true CA3156134A1 (en) 2021-04-22

Family

ID=68084722

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3156134A Pending CA3156134A1 (en) 2019-09-30 2020-09-30 Anti-tirc7 antigen binding proteins

Country Status (6)

Country Link
US (2) US12497451B2 (https=)
EP (1) EP4041766A2 (https=)
JP (1) JP7691977B2 (https=)
AU (1) AU2020367945A1 (https=)
CA (1) CA3156134A1 (https=)
WO (1) WO2021073877A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO2003054018A2 (en) * 2001-12-21 2003-07-03 Genpat77 Pharmacogenetics Ag Anti-tirc7 antibodies in therapy of inflammatory diseases
US20060165684A1 (en) * 2001-12-21 2006-07-27 Nalan Utku Therapeutic anti-tirc7 antibodies for use in immune related and other diseases

Also Published As

Publication number Publication date
WO2021073877A3 (en) 2021-07-29
JP2023504974A (ja) 2023-02-08
US20220363753A1 (en) 2022-11-17
AU2020367945A1 (en) 2022-05-12
WO2021073877A2 (en) 2021-04-22
EP4041766A2 (en) 2022-08-17
US12497451B2 (en) 2025-12-16
US20260062479A1 (en) 2026-03-05
JP7691977B2 (ja) 2025-06-12

Similar Documents

Publication Publication Date Title
Lee et al. Identification and characterization of a nuclear localization sequence-binding protein in yeast.
Blank et al. Identification, recombinant expression, and characterization of the 100 kDa high molecular weight Hymenoptera venom allergens Api m 5 and Ves v 3
EP1051432B1 (en) Method for reducing immunogenicity of proteins
Geisbrecht et al. Characterization of PECI, a novel monofunctional Δ3, Δ2-enoyl-CoA isomerase of mammalian peroxisomes
US9334487B2 (en) Methods for diagnosing rheumatoid arthritis
Singh et al. Immuno-reactive molecules identified from the secreted proteome of Aspergillus fumigatus
Hall et al. Alterations in the salivary proteome and N-glycome of Sjogren’s syndrome patients
US20200353038A1 (en) Pif-transfected cells and methods of use
HK1211701A1 (en) Method for prediction of an immune response against mismatched human leukocyte antigens
US20180243408A1 (en) Tolerance therapeutic for treating polypeptide induced allergy
JP2001507130A (ja) アレルギー性気管支肺アスペルギルス症の診断方法
JP5523108B2 (ja) 新規アレルゲンとしての前立腺カリクレイン
JPH11503610A (ja) 好酸球で発現される新規なケモカイン
Schmidt et al. Immunoaffinity targeted mass spectrometry analysis of human plasma samples reveals an imbalance of active and inactive CXCL10 in primary Sjogren’s syndrome disease patients
CA3156134A1 (en) Anti-tirc7 antigen binding proteins
Hudrisier et al. Structural and functional identification of major histocompatibility complex class I-restricted self-peptides as naturally occurring molecular mimics of viral antigens: possible role in CD8+ T cell-mediated, virus-induced autoimmune disease
EP0585960A2 (en) Diagnostic method for autoimmune diseases
Phillips et al. The mouse macrophage activation‐associated marker protein, p71/73, is an inducible prostaglandin endoperoxide synthase (cyclooxygenase)
JPH04505401A (ja) 主要組織適合抗原に会合したペプチドを認識するモノクローナル抗体
Falta et al. Metal-specific CD4+ T-cell responses induced by beryllium exposure in HLA-DP2 transgenic mice
Chapman et al. Defined epitopes: in vivo and in vitro studies using recombinant allergens
ATE472599T1 (de) Chemokin alpha-5
JPH09503125A (ja) 組み換えクラドスポリウムヘルバルム（Ｃｌａｄｏｓｐｏｒｉｕｍｈｅｒｂａｒｕｍ）アレルゲン
Albekairi et al. Design of a Multi-Epitope Vaccine against Tropheryma whipplei Using Immunoinformatics and Molecular Dynamics Simulation Techniques. Vaccines 2022, 10, 691
Lee et al. Identification of immunoglobulin E (IgE)-binding epitopes and recombinant IgE reactivities of a latex cross-reacting Indian jujube Ziz m 1 allergen

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220622

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241008

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250131

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250528

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250528

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250827

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250827

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260416

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260416

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260416